Ser330
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser330  -  GJA1 (human)

Site Information
AGstIsNsHAQPFDF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449994

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 ) , mass spectrometry ( 1 , 3 , 4 ) , mutation of modification site ( 2 ) , phospho-antibody ( 5 ) , western blotting ( 5 )
Disease tissue studied:
breast cancer ( 1 ) , lung cancer ( 3 ) , non-small cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
CK1A (human) ( 2 )

Downstream Regulation
Effects of modification on GJA1:
protein conformation ( 2 )

References 

1

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

2

Grosely R, et al. (2013) Effects of Phosphorylation on the Structure and Backbone Dynamics of the Intrinsically Disordered Connexin43 C-terminal Domain. J Biol Chem 288, 24857-70
23828237   Curated Info

3

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

4

Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313
18578522   Curated Info

5

Solan JL, Lampe PD (2007) Key connexin 43 phosphorylation events regulate the gap junction life cycle. J Membr Biol 217, 35-41
17629739   Curated Info